This comparison examines two biotechnology companies operating in overlapping yet distinct areas of the cell and gene therapy landscape. Autolus Therapeutics (AUTL) has already commercialized a T-cell therapy for a blood cancer, while CRISPR Therapeutics (CRSP) is building a gene-editing platform around the first approved CRISPR-based therapy. Investors evaluating growth-stage biotech often weigh a near-term commercial ramp against a longer-dated, broader pipeline, and this stock comparison highlights that trade-off. The analysis is most relevant to traders and long-term investors assessing relative performance, market positioning, and risk in the evolving cell and gene therapy sector.
Autolus Therapeutics is a commercial-stage biopharmaceutical company developing programmed T-cell therapies. Its marketed product, AUCATZYL (obe-cel), is approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a form of blood cancer. Recent market activity has reflected improving commercial execution: quarterly product revenue climbed roughly 119% year over year to about $45.7 million, and management raised full-year 2026 net product revenue guidance to a range of $140 million to $150 million.
Gross margin turned positive and reached approximately 55% in the most recent quarter, a notable shift for a company that previously reported losses across quarters. Sentiment has also been shaped by cost discipline, including a workforce reduction of about 13%, and a financing facility of up to $250 million. Key catalysts include longer-term data from the CARLYSLE trial in refractory lupus and initial AUTO8 data in light-chain amyloidosis, both expected by year-end. The shares have traded in a broad range, underscoring the volatility typical of smaller-cap biotech.
CRISPR Therapeutics is a gene-editing company built on the CRISPR/Cas9 platform. Its flagship therapy, Casgevy, developed with Vertex Pharmaceuticals, is approved in the United States and Europe for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Under the partnership, Vertex leads commercialization and the two companies share costs and profits on a 60/40 basis. Recent momentum has centered on Casgevy's uptake, with Vertex recording sequential and year-over-year sales growth, plus label expansion to younger patients.
Financially, CRSP reports a relatively small top line, with collaboration revenue of about $10.2 million in the most recent quarter, alongside a net loss that has narrowed from a year earlier. The company holds a substantial cash position of roughly $2.36 billion, supporting a diversified pipeline that includes CTX310 for cardiovascular indications and zugo-cel, an investigational allogeneic CAR-T therapy. Analysts broadly maintain a positive consensus rating, though shares have lagged the broader market year to date, reflecting continued clinical and commercial execution risk.
For traders seeking a systematic lens on names like AUTL and CRSP, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, but only those best suited to current market conditions earn a place in this rotating selection. These bots differ across trading styles, strategies, timeframes, performance statistics, and the sets of tickers they trade, giving investors a range of approaches to review. The page highlights available performance numbers and statistics to help users assess which automated systems are currently generating the most relevant signals. Exploring the Trending AI Robots section can help traders evaluate how algorithmic models are positioning across these and other securities.
The core contrast between these two stocks is the maturity of their commercial franchises. AUTL is executing a focused launch and expanding margins, but its business is concentrated on a single marketed therapy and a narrower indication set, with a modest cash runway relative to its larger peer. CRSP offers broader platform optionality across hematology, cardiovascular, and autoimmune disease, backed by a much larger cash balance, yet it remains deeply unprofitable with minimal reported revenue.
Growth drivers also differ: AUTL's near-term story hinges on AUCATZYL adoption and pipeline readouts in lupus and amyloidosis, while CRSP's narrative depends on Casgevy's ramp and multiple clinical milestones. Risk factors diverge accordingly, with AUTL exposed to reimbursement and manufacturing scale-up, and CRSP exposed to clinical trial outcomes and dilution from convertible financing. Sector exposure overlaps in cell therapy, but CRSP's gene-editing platform spans a wider therapeutic base.
Based on observable factors, Tickeron's AI would likely favor AUTL in the current environment for trend consistency and near-term positioning. The company's accelerating revenue, transition to positive gross margin, raised guidance, and defined catalysts offer a clearer, more measurable momentum profile than a still loss-making platform story. That said, CRSP presents stronger balance-sheet stability and greater long-term optionality, which could support relative performance over a longer horizon. The assessment is probabilistic: AUTL appears better positioned on short-term trend and commercial momentum, while CRSP's broader pipeline warrants monitoring for catalyst-driven shifts in sentiment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for AUTL moved below the 200-day moving average on November 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AUTL entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.596). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 50-day moving average for CRSP moved below the 200-day moving average on November 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 86 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.596). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AUTL | CRSP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 88 | 78 | |
P/E GROWTH RATING 1..100 | 35 | 56 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for AUTL (71). This means that CRSP’s stock grew somewhat faster than AUTL’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that CRSP’s stock grew similarly to AUTL’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as AUTL (99). This means that CRSP’s stock grew similarly to AUTL’s over the last 12 months.
CRSP's Price Growth Rating (78) in the Biotechnology industry is in the same range as AUTL (88). This means that CRSP’s stock grew similarly to AUTL’s over the last 12 months.
AUTL's P/E Growth Rating (35) in the Biotechnology industry is in the same range as CRSP (56). This means that AUTL’s stock grew similarly to CRSP’s over the last 12 months.
| AUTL | CRSP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Momentum ODDS (%) | N/A | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 80% |
| Advances ODDS (%) | 13 days ago 86% | 24 days ago 82% |
| Declines ODDS (%) | 2 days ago 88% | 5 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AUTL’s FA Score shows that 0 FA rating(s) are green while CRSP’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AUTL’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).
AUTL (@Biotechnology) experienced а -22.45% price change this week, while CRSP (@Biotechnology) price change was -7.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
AUTL is expected to report earnings on Mar 10, 2027.
CRSP is expected to report earnings on Feb 16, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To AUTL | 1D Price Change % | ||
|---|---|---|---|---|
| AUTL | 100% | -7.38% | ||
| CRSP - AUTL | 46% Loosely correlated | +0.44% | ||
| SANA - AUTL | 43% Loosely correlated | -8.62% | ||
| EDIT - AUTL | 43% Loosely correlated | -4.09% | ||
| RCKT - AUTL | 43% Loosely correlated | -7.58% | ||
| TSHA - AUTL | 43% Loosely correlated | -1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFP | 18.23 | -0.14 | -0.76% |
| FLAHERTY & CRUMRINE DYNAMIC PREFERRED AND Income FUND | |||
| FXED | 16.14 | -0.20 | -1.22% |
| Sound Enhanced Fixed Income ETF (FXED) | |||
| XBAP | 41.39 | -0.94 | -2.21% |
| Innovator U.S. Equity Accelerated 9 Buffer ETF - April (XBAP) | |||
| FPXE | 28.94 | -0.97 | -3.24% |
| First Trust IPOX Europe Equity Opportunities ETF (FPXE) | |||
| CWI | 35.79 | -1.23 | -3.32% |
| State Street SPDR MSCI ACWI ex-US ETF (CWI) | |||